An antibody-drug conjugate directed against uPARAP comprising: a. an antibody, wherein the antibody is selected from the group consisting of: i. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 9 or a sequence having at least 90% sequence identity thereto, and ii) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 10 or a sequence having at least 90% sequence identity thereto, wherein any sequence variance is outside the complementarity determining regions, ii. a humanised version of the antibody or antigen-binding fragment thereof of i., iii. a chimeric version of the antibody or antigen-binding fragment thereof of i., iv. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 6, 7 and 8, v. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 45, 46 and 47, vi. a humanised version of the antibody or antigen-binding fragment thereof of iv. or v. b. an active agent, wherein the active agent is selected from a therapeutic agent, a cytotoxic agent, a radioisotope and a detectable label, and c. a linker which links a) to b). a. an antibody, wherein the antibody is selected from the group consisting of: i. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 9 or a sequence having at least 90% sequence identity thereto, and ii) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 10 or a sequence having at least 90% sequence identity thereto, wherein any sequence variance is outside the complementarity determining regions, ii. a humanised version of the antibody or antigen-binding fragment thereof of i., iii. a chimeric version of the antibody or antigen-binding fragment thereof of i., iv. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 6, 7 and 8, v. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 45, 46 and 47, vi. a humanised version of the antibody or antigen-binding fragment thereof of iv. or v. i. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 9 or a sequence having at least 90% sequence identity thereto, and ii) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 10 or a sequence having at least 90% sequence identity thereto, wherein any sequence variance is outside the complementarity determining regions, i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 9 or a sequence having at least 90% sequence identity thereto, and ii) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 10 or a sequence having at least 90% sequence identity thereto, wherein any sequence variance is outside the complementarity determining regions, ii. a humanised version of the antibody or antigen-binding fragment thereof of i., iii. a chimeric version of the antibody or antigen-binding fragment thereof of i., iv. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 6, 7 and 8, i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 6, 7 and 8, v. an antibody or antigen-binding fragment thereof comprising i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 45, 46 and 47, i) an immunoglobulin light chain variable region comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, and ii) an immunoglobulin heavy chain variable region comprising the amino acid sequences of SEQ ID NOs 45, 46 and 47, vi. a humanised version of the antibody or antigen-binding fragment thereof of iv. or v. b. an active agent, wherein the active agent is selected from a therapeutic agent, a cytotoxic agent, a radioisotope and a detectable label, and c. a linker which links a) to b).